Margaret Gatti-Mays, MD MPH, The Ohio State University, Columbus, OH, comments on the current limitations of cancer vaccines and the emerging strategies to address them, highlighting three key platforms: DNAJB1-PRKACA fusion-based, SYNC-T in situ, and oral vaccines. She notes that they collectively draw into question whether the generation of a first immune response in patients and subsequent immunotherapy is a potential strategy. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.